Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
Clinical trial NCT02736500 · COMPLETED
Trial details
- NCT number
- NCT02736500
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-09-02
- Primary completion
- 2017-04-01
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.